During the past decade, Hospital Clínico Universitario de Valencia; Servicio de Oncología conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 8 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Clínico Universitario de Valencia; Servicio de Oncología" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "AstraZeneca" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "Celgene Corporation" with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Clínico Universitario de Valencia; Servicio de Oncología" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator, "SOLTI Breast Cancer Research Group" with 2 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Clínico Universitario de Valencia; Servicio de Oncología" are "Breast Cancer" (6 trials), "Colorectal Cancer" (2 trials), "Triple-Negative Breast Cancer" (2 trials), "Advanced Ovarian Cancer" (1 trials) and "BRCA Mutated" (1 trials). Many other conditions were trialed in "Hospital Clínico Universitario de Valencia; Servicio de Oncología" in a lesser frequency.

Most popular intervention types in "Hospital Clínico Universitario de Valencia; Servicio de Oncología" are "Drug" (20 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (8 trials), "Placebo" (7 trials), "Paclitaxel" (5 trials), "Carboplatin" (4 trials) and "Ipatasertib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Clínico Universitario de Valencia; Servicio de Oncología" are 15 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Clínico Universitario de Valencia; Servicio de Oncología". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Hospital Clínico Universitario de Valencia; Servicio de Oncología, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Clínico Universitario de Valencia; Servicio de Oncología, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".